Brief: Shanghai Henlius Biotech Signs License Agreement With FBD for HCB101
30/06/2025 11:34
June 30 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: LICENSE AGREEMENT WITH FBD FOR HCB101 FBD TO GRANT COMPANY AN EXCLUSIVE LICENSE FOR HCB101 COMPANY SHALL PAY FBD UPFRONT PAYMENT OF US$10 MILLION Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln